




PHARMACEUTICAL 2023

Werewolf Therapeutics Inc.
Rank 144 of 446





PHARMACEUTICAL 2023

Werewolf Therapeutics Inc.
Rank 144 of 446

The relative strengths and weaknesses of Werewolf Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Werewolf Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Werewolf Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 158%, being 115% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	140,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,989
Liabilities, Non-Current	13,919
Other Assets	11,057
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	18,647
Other Revenues	0
Property and Equipment	8,988
Research and Development	53,761
Selling, General and Administrative Expense	18,696

Output Variable	Value in 1000 USD
Assets	160,245
Liabilities	37,908
Expenses	72,457
Revenues	0
Stockholders Equity	122,337
Net Income	-53,810
Comprehensive Net Income	-53,810
Economic Capital Ratio	158%